Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
Rhea-AI Summary
Nutriband (NASDAQ:NTRB) has announced the exercise of warrants at a strike price of $6.43, generating gross proceeds of $5,306,000. The company will utilize these funds primarily for completing the clinical development of AVERSA Fentanyl and submitting its New Drug Application (NDA) to the FDA for marketing approval.
AVERSA Fentanyl is positioned to potentially become the first opioid patch with abuse deterrent properties. According to the Health Advances Aversa Fentanyl market analysis report 2022, the product could achieve peak annual US sales between $80 million to $200 million.
Positive
- Successful warrant exercise generating $5.3M in proceeds
- AVERSA Fentanyl potential peak sales of $80M-$200M annually
- Development of first-in-class abuse deterrent opioid patch
Negative
- Additional funding may be needed to complete clinical development and FDA submission
- FDA approval not guaranteed despite development progress
News Market Reaction
On the day this news was published, NTRB declined 1.89%, reflecting a mild negative market reaction. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $73M at that time.
Data tracked by StockTitan Argus on the day of publication.
ORLANDO, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced today that it has seen warrants exercised at a strike price of
The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fentanyl has the potential to become the world's first opioid patch with abuse deterrent properties and is estimated it could reach peak annual US sales of
1 Health Advances Aversa Fentanyl market analysis report 2022
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
How much did Nutriband (NTRB) raise through warrant exercise in September 2025?
What is the projected market potential for AVERSA Fentanyl?
What will Nutriband use the warrant exercise proceeds for?
What makes AVERSA Fentanyl unique in the market?
What is the current development stage of Nutriband's AVERSA Fentanyl?
